Synlogic announces international nonproprietary name selection for synb1934

The world health organization has approved “labafenogene marselecobac” name attributes recognize synlogic's proprietary technology  and commitment to phenylketonuria community cambridge, mass., june 28, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that the international nonproprietary names (inn) expert committee of the world health organization (who-inn) has selected "labafenogene marselecobac" for the nonproprietary name of the company's investigational drug for phenylketonuria (pku), previously known as synb1934.
SYBX Ratings Summary
SYBX Quant Ranking